On our way to targeted therapy for cachexia in cancer?

Current Opinion in Oncology

Volumn 18, Issue 4, 2006, Pages 335-340

  Boddaert, Manon S A ^a   Gerritsen, Winald R ^a   Pinedo, Herbert M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cachexia; Cancer; Pathogenesis; Targeted therapy

Indexed keywords

APPETITE STIMULANT; BORTEZOMIB; CORTICOSTEROID; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; CYTOKINE ANTIBODY; DEHYDROXYMETHYLEPOXYQUINOMICIN; FISH OIL; GESTAGEN; I KAPPA B; ICOSAPENTAENOIC ACID; INTERLEUKIN 12; INTERLEUKIN 15; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MELATONIN; OMEGA 3 FATTY ACID; PARVOVIRUS VECTOR; PENTOXIFYLLINE; PHYTOALEXIN; RESVERATROL; SALICYLATE SODIUM; SOMATOMEDIN C; THALIDOMIDE; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ANOREXIA; BODY MASS; CACHEXIA; CANCER; CATABOLISM; CLINICAL TRIAL; DIET THERAPY; DIETARY INTAKE; ENERGY EXPENDITURE; ESOPHAGUS CANCER; HOMEOSTASIS; HUMAN; MOLECULAR BIOLOGY; MUSCLE ATROPHY; NONHUMAN; PANCREAS CANCER; PATHOGENESIS; PATHOGENICITY; PERIPHERAL EDEMA; PHYSIOLOGY; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKELETAL MUSCLE; TRANSCRIPTION INITIATION; VEIN THROMBOSIS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WATER RETENTION; WITHDRAWAL SYNDROME;

ANTINEOPLASTIC AGENTS; APPETITE DEPRESSANTS; CACHEXIA; CYTOKINES; HUMANS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASMS;

EID: 33748059538     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000228738.85626.ac     Document Type: Review

References (51)

1. Tisdale MJ. Cachexia in cancer patients. Nature 2002; 2:862-870.
2. Hockley JM, Dunlop R, Davies RJ. Survey of distressing symptoms in dying patients and their families in hospital and the response to a symptom control team. BMJ 1988; 296:1715-1717.
3. Tisdale MJ. Biology of cachexia. J Nat Cancer Inst 1997; 89:1763-1773.
4. Bruera ED. ABC of palliative care: anorexia, cachexia and nutrition. BMJ 1997; 315:1219-1222.
5. Evans WK, Nixon DW, Daly JM, et al. A randomized trial of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal cancer and non-small-cell lung cancer. J Clin Oncol 1987; 5:113-124.
6. Ovesen L, Allingstrup L, Hannibal J, et al. Effect of dietary counseling on food intake, body weight, response rate, survival and quality of life in cancer patients undergoing chemotherapy: a prospective randomized study. J Clin Oncol 1993; 11:2043-2049.
7. Klein S, Kinney J, Jeejeebhoy K, et al. Nutrition support in clinical practice: review of published data and recommendations for future research directions. Summary of a conference sponsored by the National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition. Am J Clin Nutr 1997; 66:683-706.
8. Jaskowiak NT, Alexander HR. The pathophysiology of cancer cachexia. In: Doyle D, Hanks GWC, MacDonald N, editors. Oxford textbook of palliative medicine. Oxford: Oxford University Press; 1998. pp. 534-548.
9. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
10. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 2003; 5:87-90.
11. Jagoe RT, Goldberg AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 2001; 4:183-190.
12. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294:1704-1708.
13. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001; 3:1014-1019.
14. Gomes MD, Lecker SH, Jagoe RT, et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001; 98:14440-14445.
15. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14:395-403.
16. Cai D, Frantz JD, Tawa NE, et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 2004; 119:285-298.
17. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117:399-412.
18. Tisdale M. Molecular pathways leading to cachexia. Physiology 2005; 20:340-348.
19. Lundholm K, Bylund AC, Holm J, et al. Skeletal muscle metabolism in patients with malignant tumour. Eur J Cancer 1976; 12:465-473.
20. Lundholm K, Bennegard K, Eden E, et al. Efflux of 3-methylhistidine from the leg of cancer patients who experience weight loss. Cancer Res 1982; 42:4809-4818.
21. Attaix D, Aurousseau E, Combaret L, et al. Ubiquitin - proteasome dependent proteolysis in skeletal muscle. Reprod Nutr Dev 1998; 38:153-165.
22. Li Y-P, Schwartz RJ, Waddell ID, et al. Skeletal muscle myotubes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumour necrosis factor α. FASEB J 1998; 12:871-880.
23. Acharyya S, Ladner KJ, Nelsen LL, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004; 114:370-378.
24. Todorov P, Cariuk P, McDevitt T, et al. Characterization of a cancer cachectic factor. Nature 1996; 379:739-742.
25. Gelin J, Moldawer LL, Lonnroth C, et al. Role of endogenous tumour necrosis factor alpha and interleukin 1 for experimental tumour growth and the development of cancer cachexia. Cancer Res 1991; 51:415-421.
26. Wyke SM, Tisdale MJ. NF-κB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br J Cancer 2005; 92:711-721. Study showing that protein degradation in skeletal muscle through tumour-derived PIF is also NF-κB-mediated.
27. Guttridge DC, Mayo MW, Madris LV, et al. NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289:2363-2366.
28. Ladner KJ, Caligiuri MA, Guttridge DC. Tumour necrosis factor-regulated biphasic activation of NF-κB is required for cytokine-induced loss of skeletal muscle gene products. J Biol Chem 2003; 278:2294-2303.
29. Megeney LA, Kablar B, Garrett K, et al. MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev 1996; 10:1173-1183.
30. Di Marco S, Mazroui R, Dallaire P, et al. NF-κB-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Mol Cell Biol 2005; 25:6533-6545. Identification of another NF-κB-mediated pathway, in addition to the ubiquitin proteasome proteolytic pathway, leading to muscle wasting, thus establishing new potential therapeutic targets.
31. Muscaritoli M, Bossola M, Aversa Z, et al. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 2006; 42:31-41. Clear and insightful review introducing the use of IGF-1 in combination with gene therapy as a potential new therapy. Great graphics!
32. Pascual López A, Roqué I, Figuls M, et al. Systemic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004; 27:360-369.
33. Simons JP, Schols AJWJ, Hoefnagels JMJ, et al. Effects of medroxyprogesterone acetate on food intake, body composition and resting energy expenditure in patients with advanced non-hormone-sensitive cancer. Cancer 1998; 82:553-560.
34. Mantovani G, Maccio A, Lai P, et al. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogestrone acetate. Semin Oncol 1998; 25:45-52.
35. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megesterol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17:3299-3306.
36. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megesterol acetate versus combination therapy for cancer-associated anorexia. J Clin ncol 2002; 20:567-573.
37. Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004; 22:2469-2476.
38. Moertel CG, Schutt AJ, Reitmeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33:1607-1609.
39. Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer. BMJ 1984; 288:27.
40. Kahn ZH, Simpson E, Cole AT, et al. Oesophageal cancer and cachexia: the effect of short term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 2003; 17:677-682.
41. Gordon JN, TrebbleTM. Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomized placebo-controlled trial. Gut 2005; 54:540-545. First randomized controlled trial for this indication of thalidomide. Positive results may make thalidomide part of an integrated intervention to treat cancer cachexia in the future.
42. Wyke SM, Russell ST, Tisdale MJ. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-κB activation. Br J Cancer 2004; 91:1742-1750.
43. Kuroda K, Horiguchi Y, Nakashima J, et al. Prevention of cancer cachexia by a novel nuclear factor κB inhibitor in prostate cancer. Clin Cancer Res 2005; 11:5590-5594.
44. Whitehouse AS, Smith HJ, Drake JL, et al. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res 2001; 61:3604-3609.
45. Tisdale MJ. Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia. Nutrition 1996; 12:S31-S33.
46. Barber MD, Ross JA, Voss AC, et al. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999; 81:80-86.
47. Gogos CA, Ginopoulos P, Salsa B, et al. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy. Cancer 1998; 82:395-402.
48. Fearon KCH, von Meyenfeldt MF, Moses AGW, et al. Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomized double blind trial. Gut 2003; 52:1479-1486.
49. Bunn PA Jr. The potential role of proteasome inhibitors in the treatment of lung cancer. Clin Cancer Res 2004; 10:4263s-4265s.
50. Barton-Davis ER, Shoturma DI, Musaro A, et al. Viral mediated expression of insulin-like growth factor-1 blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci U S A 1998; 95:15603-15607.
51. Ryther RCC, Flynt AS, Phillips JA, et al. SiRNA therapeutics: big potential from small RNAs. Gene Ther 2005; 12:5-11.